SOT 59th Annual Meeting and ToxExpo 2020 | InSphero

SOT 59th Annual Meeting and ToxExpo 2020


Mar 15 - 19, 2020

The Next Best Thing to Human

Meet InSphero Toxicology and 3D cell-based assay experts at SOT 2020 to learn how you can screen for toxic compounds earlier with the 3D™ InSight Liver Toxicology Platform and translational safety solutions.

  • Achieve 2X sensitivity in DILI prediction without sacrificing specificity
  • Minimize risks late-stage market withdrawal
  • Rely on ISO 9001:2015 quality-controlled microtissues
  • Reduce animal testing with pharma-validated 3D liver models
  • Learn about new 3D causality assays for functional validation of DILI mechanisms

Schedule a Meeting

Enabling sensitive DILI prediction through the presence of DILI-relevant biological pathways and exposure settings (1-5)

Tease out Mechanisms of Toxicity

Talk to our team at SOT to discuss how we can work for you. Our 3D InSight™ Toxicology Platform combines the predictive power of our physiologically relevant liver models with the applications expertise of our scientific staff.

  • Standardized DILI Screening
  • Custom Mechanistic & Investigative Studies
  • 3D-optimizined causality assays for assessing effects of reactive metabolites and oxygen species
  • Mitochondrial Tox
  • Pancreatic Endocrine Toxicity

Conference Detail

SOT 2020 ToxExpo
March 15-19, 2020
Anaheim Convention Center
Anaheim, CA USA

Program Information
View the SOT 2020 Program
Download SOT 2020 Event App

  • InSphero Booth: 1533

jump to section
jump to section

Oral Presentations

Exhibitor Hosted Session

Monday, March 16, 12 – 1 PM, Room 206A

Transforming Translational Safety and Mechanistic Toxicology with 3D Human Liver Microtissues

Chair: Prof. Armin Wolf; Presenter: Monika Kijanska
Accurately predicting the human response to drug treatment remains one of the biggest challenges in drug safety programs. We will discuss new screening strategies and novel applications for 3D human liver microtissues that complement traditional testing programs, while providing deeper insights into mechanisms and biomarkers of DILI.

Exhibitor Hosted Session

Tuesday, March 17, 1:30 – 2:30 PM, Room 206A
Redefining NASH Drug Discovery: A New Approach to Complex Disease Modeling
Chair: Prof. Armin Wolf; Presenter: Sue Grepper
Non-alcoholic steatohepatitis (NASH) is a progressive disease that takes years to develop in humans and involves an intricate interplay of multiple liver cell types, impaired liver functionality, and disrupted signaling. We will present a versatile platform for screening/testing NASH therapies using pathophysiological relevant, disease-tunable 3D in vitro human models.

Poster Presentations

Session: Alternatives to Mammalian Models I

Monday, March 16, 10:45 AM – 12:30 PM, Exhibit Hall
Poster Number: 1377|P457
Presenting Author: Julie Harney, Pfizer Inc.
Title: Evaluation of AAV Transduction Efficacy among Novel Human and Money In Vitro Liver Models

Session: Safety Assessment Pharmaceutical – Drug Discovery

Monday, March 16, 10:45 AM – 12:30 PM, Exhibit Hall
Poster Number: 1687|P834
Presenting Author: Sue Grepper, InSphero
Title: Establishment of a 3D Human NASH Model for High-throughput Drug Efficacy Testing

Session: Safety Assessment Pharmaceutical – Drug Discovery

Monday, March 16, 10:45 AM – 12:30 PM, Exhibit Hall
Poster Number: 1690|P837
Presenting Author: Monika Kijanska, InSphero
Title: Novel 3D Liver Microtissue Reactivity Assay Reveals Causal Link between Glutathione Status and Cytotoxicity

InSphero In-Booth Posters

March 11-13, during exhibit hours, ToxExpo Booth 1533

  • 3D InSight™ Liver Toxicology Platform
  • 3D InSight™ Human Liver Disease Platform
  • Predict DILI with Confidence
  • Translational Safety for Drug Development
  • Akura™ Flow Scalable Organ-on-a-Chip platform
  • Akura™ 96 and 384 Plate Technologies